We are creating a fully-integrated biotechnology company committed to the development and commercialization of novel Surfactant Replacement Therapies (SRTs™) with potential application across the respiratory disease continuum. Surfactant is produced naturally in the lungs and is essential for normal breathing throughout life. Our product platform is based on a novel pulmonary surfactant technology intended to establish a completely new, therapeutic approach in the treatment of respiratory disease, with a targeted initial application in premature infants.

Our Mission

Through innovative science, we will save and improve the lives of the most fragile patients by advancing the standard of pulmonary medicine, leading with our surfactant technology. We will provide our dedicated employees with a rewarding work experience, work side-by-side with the healthcare community and create value for our shareholders.

Recent News

September 3, 2008
Discovery Labs’ Aerosolized KL-4 Surfactant Selected for Evaluation in Phase 2a Cystic Fibrosis Clinical Trial

August 6, 2008
Discovery Labs Reports Progress in Responding to Surfaxin FDA Approvable Letter